{
    "symbol": "CNCE",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-07 09:58:04",
    "content": " After releasing top line data from our first pivotal clinical trial in the second quarter of 2022, this past August we released top line results from THRIVE-AA2, and in September we presented additional results from THRIVE-AA1 during the late breaking news session at the EADV Congress in Milan. Importantly, we now have over three years of deuruxolitinib treatment experience in some of the patients participating in the open label extension study, giving us a sizable safety database to support our planned NDA filing in the first half of 2023 and supporting future commercialization. Your line is open. One moment for our next question. Your line is open. One moment for our next question. Your line is open. One moment for our next question. Your line is open. One moment for our next question."
}